Synairgen raises £80m after Covid-19 treatment shows progress
Synairgen, the UK biopharmaceuticals company, has raised £80m from investors to fund the next stage of clinical trials for a treatment designed to alleviate the respiratory symptoms of Covid-19.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: